Cost-effectiveness of lapatinib plus capecitabine (LAP plus C) versus capecitabine alone (C-only) or trastuzumab plus capecitabine (TZ plus C) in women with HER2-positive metastatic breast cancer (MBC) who have received prior therapy with trastuzumab (TZ) from the UK National Health Service (NHS) perspective

被引：0
|
作者：
Sofrygin, O.
Delea, T. E.
Tappenden, P.
Karnon, J.
Browning, D.
Amonkar, M.
Lykopoulos, K.
Cameron, D. A.
机构：
[1] Policy Anal Inc, Brookline, MA USA
[2] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England
[3] Univ Adelaide, Dept Publ Hlth, Adelaide, SA, Australia
[4] GlaxoSmithKline Hlth Outcomes Oncol, London, England
[5] GlaxoSmithKline, Collegeville, PA USA
[6] GlaxoSmithKline Global Hlth Outcomes, London, England
[7] Univ Edinburgh, Edinburgh, Midlothian, Scotland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.6037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6037
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Lapatinib (L) plus capecitabine (C) in HER2+metastatic breast cancer (MBC): exploratory analyses by prior therapy
    Crown, J.
    Casey, M. A.
    Cameron, D.
    Newstat, B.
    Stein, S. H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 285 - 285
  • [12] Trastuzumab-Emtansine versus Capecitabine plus Lapatinib in Patients with previously treated HER2-positive metastatic Breast Cancer
    Ruckhaeberle, Eugen
    ONKOLOGE, 2017, 23 (11): : 940 - 942
  • [13] A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP
    Takano, Toshimi
    Tsurutani, Junji
    Takahashi, Masato
    Yamanaka, Takeharu
    Sakai, Kazuko
    Ito, Yoshinori
    Fukuoka, Junya
    Kimura, Hideharu
    Kawabata, Hidetaka
    Tamura, Kenji
    Matsumoto, Koji
    Aogi, Kenjiro
    Sato, Kazuhiko
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    Saeki, Toshiaki
    BREAST, 2018, 40 : 67 - 75
  • [14] Validity of proportional hazards (PH) Weibull models for analyzing progression free survival (PFS) and overall survival (OS) in patients with trastuzumab (TZ)-refractory ERBB2+(HER2+) metastatic breast cancer (MBC) receiving lapatinib plus capecitabine (L+C) versus capecitabine only (C-only)
    Sofrygin, O.
    Delea, T.
    Tappenden, P.
    Karnon, J.
    Amonkar, M. M.
    Walker, M.
    VALUE IN HEALTH, 2008, 11 (03) : A57 - A57
  • [15] Effect of lapatinib plus capecitabine (L plus C) on quality of life (QOL) compared to capecitabine (C) alone in ErbB2+metastatic breast cancer (MBC): An exploratory analysis
    Zhou, X.
    Segreti, A.
    Cameron, D.
    Geyer, C. E.
    Cella, D.
    Amonkar, M.
    Stein, S.
    Walker, M. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [16] Rechallenge of trastuzumab-based therapy in HER2-positive breast cancer patients who progressed after lapatinib plus capecitabine
    Khanmammadov, Nijat
    Dogan, Izzet
    Khishigsuren, Bayarmaa
    Azizy, Abdulmunir
    Saip, Pinar
    Aydiner, Adnan
    MEDICINE, 2025, 104 (06)
  • [17] LAPATINIB (L) PLUS CAPECITABINE (C) IN HER2-POSITIVE METASTATIC BREAST CANCER (MBC): AN EXPLORATORY ANALYSIS OF OVERALL SURVIVAL (OS) BASED ON POSTSTUDY THERAPY
    Crown, J. P.
    Casey, M.
    Cameron, D.
    Chan, A.
    Geyer, C. E.
    ANNALS OF ONCOLOGY, 2010, 21 : 101 - 101
  • [18] Lapatinib Plus Capecitabine in Trastuzumab Pre-Treated HER2-Positive Metastatic Breast Cancer: The Canadian Lapatinib Expanded Access Program Experience
    Chang, J.
    Chia, S.
    Prady, C.
    Haider, K.
    Grenier, D.
    Lopez, P.
    Ghedira, S.
    CANCER RESEARCH, 2010, 70
  • [19] WJOG6110B (ELTOP): Randomized phase II trial comparing trastuzumab plus capecitabine (HX) and lapatinib plus capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes
    Takano, Toshimi
    Kimura, Hideharu
    Nishio, Kazuto
    Yamanaka, Takeharu
    Ito, Yoshinori
    Fukuoka, Junya
    Tsurutani, Junji
    Shigeoka, Yasushi
    Uehara, Masahiro
    Sato, Kazuhiko
    Nakamura, Shinichiro
    Nakanishi, Yoichi
    Saeki, Toshiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [20] Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane
    O'Shaughnessy, Joyce
    Schwartzberg, Lee
    Piccart, Martine
    Rugo, Hope S.
    Yardley, Denise A.
    Cortes, Javier
    Untch, Michael
    Harbeck, Nadia
    Wright, Gail S.
    Bondarenko, Igor
    Glaspy, John
    Nowecki, Zbigniew
    Kayali, Fadi
    Chan, Arlene
    Levy, Christelle
    Liu, Mei-Ching
    Kim, Sung-Bae
    Lemieux, Julie
    Manikhas, Alexey
    Tolaney, Sara
    Lim, Elaine
    Gombos, Andrea
    Stradella, Agostina
    Pegram, Mark
    Fasching, Peter
    Mangel, Laszlo
    Semiglazov, Vladimir
    Dieras, Veronique
    Gianni, Luca
    Danso, Michael A.
    Vacirca, Jeff
    Kroll, Stew
    O'Connell, Joseph
    Tang, Kevin
    Wei, Thomas
    Seidman, Andrew
    CANCER RESEARCH, 2021, 81 (04)
12345